Allogene started life with a suite of ready-made candidates—along with a whopping $300 million series A round and former Kite Pharma executives Arie Belldegrun and David Chang as co-founders.
With $225 million from TPG Capital and Vida Ventures and $10 million from its founders and board members, AskBio will ramp up clinical trials and manufacturing.
